Current Scenario of Pharmacovigilance of Herbal Formulations in India

Manvir Kaur[1], Akashdeep Singh[1], Barinderjit Kaur[2], Amrinder Kaur[3], Vandna Kalsi[1*]

[1]Department of Pharmacognosy, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India

[2]Department of Pharmacology, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India

[3]Department of Ayurveda, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India

ABSTRACT

Pharmacovigilance implies the science and the exercises involved identified with the location, comprehension, appraisal and anticipation of adverse medication responses or ill effects of drugs and drug safety troubles. The main objective is to prevent human beings from the harmful consequences of the drugs. It promotes the safety and effective use of health products. It plays its vital role in meeting the ever increasing challenges in the safer use of the drugs. It is a control that is liable for patient wellbeing and is seen as a fundamental part of pharmaceutical industry. It is helpful in every therapeutic area as in cardiology, general prescription, respiratory, oncology and endocrinology. Remedies have negative effects and these ought to be seen well while administrating a prescription.

Keywords: Pharmacovigilance, herbal drugs, adverse drug reaction, herbal formulations

INTRODUCTION

Pharmacovigilance

Pharmacovigilance is the science which involves exercises responsible for the recognition, comprehension, appraisal and avoidance of un-favourable impacts of medication related issues [1]. It tends to be characterized as investigation of security of promoted drugs in large communities [2]. This science rotates around antagonistic drug reactions (ADRs). It is described as any adverse response to a medicine which is lethal and unintended [3]. Prescription issues, for instance, overdose, misuse and abuse of a medicine are considered in the pharamacovigilance study. It is a discipline that is responsible for patient wellbeing and is viewed as an essential part of pharmaceutical industry. It is applicable to every therapeutic area, for example, cardiology, general prescription, oncology, respiratory, and endocrinology. Prescriptions have unfavorable impacts and these should be seen well while administrating a medication [4].

Scope of Pharmacovigilance

a. **Patient care:** To improve quiet consideration and wellbeing corresponding to prescriptions, therapeutic and paramedical intercessions.

b. **Public health:** To deal with general wellbeing comparable to organization and utilization of drugs [5].

c. **Risk benefit assessment:** To add to evaluation of harm, favourable position, risk and feasibility of solutions.

d. **Communication:** To advance clinical preparing and successful correspondence to wellbeing experts and people in general [6].

Pharmacovigilance Centres

a. National Pharmacovigilance Centre

b. National Spontaneous Reporting system

c. National Database [7]

d. National ADR or Pharmacovigilance Advisory Committee

e. Communication Strategy [8]



Figure 1: Pharmacovigilance Services

Adverse Drug Reactions

It is an unintended response that occurs at dosages normally used in human beings. The dosage may be used for prophylaxis, diagnosis or therapy for the disease. It may also modify the physiological functions [9].

Sensitivities, peculiarities, pharmacological and toxicological components, and interactions between various medications were additional parameters used for framing the definition. The previous was later adjusted by the ICH-GCP as their meaning of an ADR [10].



Figure 2: Types of ADR's

Drugs Recalled from the Market

Table 1: Drugs recalled due to adverse reactions [11]

S.No.	NAME OF MEDICINE	THERAPEUTIC USE	REASON	YEAR
1.	Thalidomide	Hypnotic and antiemetic	Major birth defects	1961-62
2.	Elixir Sulphanilamide	Streptococcal infection	Mass poisoning	1973
3.	Zomax	Antipyretic	Allergy	1983
4.	Triazolam	CNS depressant	Change in brain chemistry	1991
5.	Cisapride	Increase motility in GIT	Cardiac arrhythmias	2000
6.	Kava kava	Antianxiety	Liver toxicity	2001
7.	Rofecoxib	NSAIDs	Cardiovascular risks	2004
8.	Valdecoxib	NSAIDs	Stevens-Johnson syndrome	2005
9.	Lumiracoxib	NSAIDs	Hepatotoxicity	2008
10.	Rosigltazone	Antidiabetic	Cardiovascular disorders	2010
11.	Sibutramine	Appetite suppressant	Cardiovascular disorders	2010

12.	Orciprenaline	Bronchodilator	Cardiovascular risks	2010
13.	Propoxyphene	Analgesic	Fatal heart rhythm abnormality	2015
14.	Losartan	High blood pressure treatment	contains N-Methylnitrosobutyric acid (recall)	2019
15.	Ranitidine	Decrease stomach acid production	Contains a nitrosamine impurity (recall)	2019

Terminology

Table 2: Definitions [12]

Term	Definition
Herbal Remedy	A therapeutic drug comprising of a substance delivered by exposing a plant or plants to drying, squashing or some other procedure, or of a blend whose sole fixings are at least two substances so created, or of a blend whose sole fixings are at least one substance so delivered and water or some other inactive substances.
Herbal Substance	All mostly entire, divided or cut plants, or their parts, green growth, organisms, lichen in a natural, typically dried structure. Certain exudates that have not been exposed to any particular treatment are likewise viewed as herbal substances. Natural substances are definitely characterized by the plant part utilized and the plant name as indicated by the binomial nomenclature (family, species, assortment and creator).
Herbal Preparation	Preparations acquired by exposing herbal substances to medications, for example, extraction, refining, articulation, fractionation, sanitization, focus and aging. These incorporate comminuted or powdered natural substances, tinctures, extricates, basic oils, communicated squeezes and handled exudates.
Herbal Medicinal Product	Any therapeutic product, containing as dynamic fixings at least one herbal substances or at least one natural ingredients, or at least one such herbal substance in blend with at least one such herbal substance.
Herbal Constituent	Chemical compound present in an herbal ingredient specifically.
Herbal Ingredient	Medicinal plant or part of plant in an herbal medicine specifically.

Regulations of Herbal Drug Medicines

Herbal prescriptions in India are subject to control under the 1940 Drugs and Cosmetics Act (D and C Act) and the 1945 Drugs and Cosmetics Rules. They regulate the manufacture, import, dispensing of pharmaceutical goods and cosmetics and sale. In 1959, the Indian government amended the Drugs and Cosmetics Act (D and C act) to include drugs which are derived from the traditional Indian medicines. None of the drugs can be delivered from a regular framework in the absence of a license issued from the State Drug Control Authorities. Prohibitive remedies and Patented drugs obtained from the usual system should include fixings listed in the obvious books as set out in the D and C Act. Ministry of Health and Family Welfare publishes pharmacopoeias which includes set standards for herbal drugs administration. Herbal medicines are regulated by Ministry of AYUSH.

In 1993, Indian government appointed a board to develop requirements for the suitability of traditional drugs that had to be incorporated into the Drugs and Cosmetics Act regulations. It prescribed that no new natural prescriptions, other than those endorsed by the authorizing specialists will be allowed to be made or advanced, besides those referenced to and created in accordance with the formulae given in the "legitimate" books for Ayurveda, Siddha and Unani herbal medicines [13].

Pharmacovigilance for Herbal Medicines

Pharmacovigilance, a French expression referring to distinguishing side effects of medications, their treatment, documentation, reportage and administrative choices dependent on them, is an established science in the developed world [13]. It is the investigation of social occasion, checking, asking about, looking over and surveying information from human services providers and patients on the hostile effects of drugs, natural things, home developed medications and customary prescriptions. Pharmacovigilance is a request including ID, evaluation and balancing activity of grievous effects of medications [14, 15].

These medicines have endured genuine testing and a huge number of long periods of human testing. A few medications have been suspended because of their toxicity, while others have been changed or joined with extra herbs to balance reactions and decrease side effects [16]. Numerous herbs have experienced changes in their uses. Studies directed on the herbs and their belongings continue changing their potential uses [17].

Table 3: List of unapproved Ayurvedic medicines [18]

S. No.	DRUG	COMPANY
1.	Tablets of Karela	Shriji Herbal Products, India
2.	Capsules of Karela	Himalaya Drug, India
3.	Capsules of Karela	Charantia,UK
4.	Powder of Maha Sudarshan Churna	Zandu Pharmaceuticals, India
5.	Powder of Maha Sudarshan Churna	Chattarisha, India

6.	Powder of Maha Sudarshan Churna	Dabur, India
7.	Safi Liquid	Hamdard, India
8.	Safi Liquid	Hamdard, Pakistan
9.	Yograj Guggul Tablets	Zandu Pharmaceuticals, India
10.	Capsules of Shilajit	Dabur, India

Problems with herbal medicines



Figure 3: Problems with herbal medicines

Need for pharmacovigilance of herbal medicines

To ensure consistency in the naming of herbs in adverse response (AR) reports, the WHO Collaborating Center for International Drug Monitoring proposed the use of appropriate logical names for prescribed herbs, including the use of such names (where this information is open) in the coding of AR reports [19]. This would ensure similarity between reports from various widespread pharmacovigilance databases. It is comparably noteworthy for the makers of disseminated AR case reports to recognize the specific items included, including name and

producer information, unequivocal fixings, and bit used. Distributed case reports would likewise profit by examination of the speculate item utilized, for sullying and contaminated, or species distinguishing proof, where conceivable [20].

A few nations acknowledge customary, experience-based proof while others consider herbal remedies as hazardous [21]. Therapeutic herbs as potential source of therapeutics aids have achieved a noteworthy job in medicinal services framework everywhere throughout the world for people in the unhealthy condition as well as potential material for keeping up appropriate well-being [22].

Methods of Pharmacovigilance of Herbal Medicines

Scopes of strategies are utilized for post marketing monitoring of medication safety including unconstrained detailing and herbal remedy prescription checking. Safety of prescriptions is normally observed through unconstrained detailing frameworks [12]. Standardized reports are utilized for revealing of suspected adverse response to regulatory authorities including doctors, drug specialists, and medical attendants and in certain nations, by shopkeepers [23]. The reports are of suspected adverse reactions, and a reporter doesn't need to affirm the relationship among medication and impact [24]. Spontaneous reports are bound to be successful where items are managed as medicines and furthermore where items are provided by health experts who are all around educated in the utilization of this reporting framework [25].



Figure 4: Methods of pharmacovigilance

Counteractive Action of Adverse Reactions to Herbal Medicines

The achievement in any pharmacovigilance system is in the capacity to counteract further unfriendly responses effectively by comprehension and utilizing the data gathered. With Ayurvedic formulations, the difficulties would be at different levels.

- Correspondence between the professionals and strategy makers of orthodox Western drug and conventional Indian drug is not satisfactory. Many professionals do not know about the need of report and where to report actually.
- Patients are not enough aware that Ayurvedic prescriptions can cause unfavourable responses and can take medications for a considerable length of time without observing as they accept that these medications do not have any side effects. Consequently, they do not provide a history of taking these medications.
- Training in Ayurveda or modern drug at both under-graduate and post-graduate levels doesn't cover pharmacovigilance of Ayurvedic medications, therefore never uncovering the young doctors to this concept.
- The Ayurvedic pharmaceutical industry isn't persuaded to concentrate on pharmacovigilance of Ayurvedic medications. Henceforth, there is no endeavour in producing security information either previously or in the wake of promotion of the formulation [26].

CONCLUSION

Pharmacovigilance is one of the important parts of healthcare systems worldwide. Each country has its own system of pharmacovigilance, but the actual fact is that number of adverse drug reactions is much higher than the number that is being reported currently. WHO is playing a vital and crucial role in pharmacovigilance operations and it also provides technical support for reporting the adverse drug reactions. A significant level of ability is required to identify the medication hazards as this has become a significant and indispensable piece of clinical research, yet it is confronting significant difficulties for better wellbeing and observing of the medications. It can function as an ace key for checking the safety of the medications. The need of great importance is that we need to accomplish the essential objective of pharmacovigilance which would be possible by engaging the national controllers and worldwide associations.

REFERENCES

1. Pharmacovigilance. Retrieved 21 September 2019, from https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/, 2019.
2. R.D. Mann, and E. B., Andrews, “Pharmacovigilance,” 2nd edition (2007). John Wiley & Sons Ltd. pp. 3, 2007.
3. World Health Organization. The importance of pharmacovigilance, 2002.
4. R.H. Meyboom, A.C. Egberts, F.W. Gribnau, and Y.A. Hekster, “Pharmacovigilance in perspective,” Drug Safety, vol. 21(6), pp. 429-447, 1999
5. S. S. Shuka, B. Gidwani, R. Pandey, S.P. Rao, V. Singh, and A. Vyas, “Importance of pharmacovigilance in Indian pharmaceutical industry,” Asian J Res Pharm Sci, vol. 2(1), pp. 4-8, 2012.

6. S. Najafi, "Importance of pharmacovigilance and the role of healthcare professionals," J Pharmacovigilance, vol. 6, pp. 252, 2018.
7. K. Maigetter, A.M. Pollock, A. Kadam, K. Ward, and M.G. Weiss, "Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements," Int J Health Policy and Mgmt, vol. 4(5), pp. 295, 2015.
8. B.H. Jadav, K.C. Thula, and D.G. Maheshwari, "Regulatory requirements of pharmacovigilance system and its comparison in India and USA," J Global Trends Pharm Sci, vol. 6(1), pp. 2351-2356, 2015.
9. I.R. Edwards, and J.K. Aronson, "Adverse drug reactions: definitions, diagnosis, and management," The Lancet, vol. 356(9237), pp. 1255-1259, 2000.
10. M. Pirmohamed, A.M. Breckenridge, N.R. Kitteringham, and B.K. Park, "Adverse drug reactions," British Med J, vol. 316(7140), pp. 1295-1298, 1998.
11. P.M. Coloma, G. Trifiro, V. Patadia, and M. Sturkenboom, "Postmarketing safety surveillance," Drug safety, vol. 36(3), pp. 183-197, 2013.
12. J. Barnes, "Pharmacovigilance of herbal medicines," Drug Saf, vol. 26(12), pp. 829-851, 2003.
13. H.Z. Toklu, "Pharmacovigilance of herbal medicine: Herbavigilance," Adv Pharmacoepidemiol Drug Saf, vol. 5(4), pp. 1-3, 2016.
14. P. Nainwal, "Pharmacovigilance of herbal medicines: an intangible approach," Int J Pharma Sci Res, vol. 1(11), pp. 45- 50, 2010.
15. D. Shaw, L. Graeme, D. Pierre, W. Elizabeth, and C. Kelvin, "Pharmacovigilance of herbal medicine. Journal of Ethnopharmacology, vol. 140(3), pp. 513-518, 2012.
16. E. Rodrigues, and J. Barnes, "Pharmacovigilance of herbal medicines," Drug Saf, vol. 36(1), pp. 1-12, 2013.
17. K. Gromek, N. Drumond, and P. Simas, "Pharmacovigilance of herbal medicines," Int J Risk Saf Med, vol. 27(2), pp. 55-65, 2015.
18. P. Wal, A., Wal, S. Gupta, G. Sharma, and A.K. Rai, "Pharmacovigilance of herbal products in India," J Young Pharmacists, vol. 3, pp. 256-258, 2011.
19. W.K. Amery, "Why there is a need for pharmacovigilance," Pharmacoepidemiol Drug Saf, vol. 8(1), pp. 61-64, 1999.
20. U. Thatte, and S. Bhalerao, "Pharmacovigilance of ayurvedic medicines in India," Indian J Pharmacol, vol. 40(Suppl1), pp. S10, 2008.
21. R. Chakraverty, and A. Banerjee, "Emerging issues in pharmacovigilance of herbal medicines in India," Int J Pharm Sci, vol. 20, pp. 40-42, 2013.
22. I.R. Edwards, "The accelerating need for pharmacovigilance," J R Coll Physicians Lond, vol. 34(1), pp. 48-51, 2000.

23. K. Haerian, D. Varn, S. Vaidya, L. Ena, H.S. Chase, and C. Friedman, "Detection of pharmacovigilance- related adverse events using electronic health records and automated methods," Clin Pharmacol Ther, vol. 92(2), pp. 228-234, 2012.
24. L. Harmark, and A.C. Van Grootheest, "Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol, vol. 64(8), pp. 743-752, 2008.
25. M. Hauben, and X. Zhou, "Quantitative methods in pharmacovigilance: focus on signal detection," Drug Saf, vol. 26(3), pp. 159-186, 2003.
26. D.L. Clouatre, "Kava kava: examining new reports of toxicity," Toxicol Lett, vol. 150(1), pp. 85-96, 2004.